Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH

Naga Chalasani, Erik J. Tillman, Sonja K. Billes, Timothy Rolph, Mazen Noureddin

Open source

DOI: 10.1097/hep.0000000000001792
Published: 2026-05-12
Container: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hep.0000000000001792,
  title = {Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH},
  author = {Naga Chalasani and Erik J. Tillman and Sonja K. Billes and Timothy Rolph and Mazen Noureddin},
  year = {2026},
  journal = {Hepatology},
  doi = {10.1097/hep.0000000000001792},
  url = {https://doi.org/10.1097/hep.0000000000001792}
}

RIS

TY  - JOUR
TI  - Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH
AU  - Naga Chalasani
AU  - Erik J. Tillman
AU  - Sonja K. Billes
AU  - Timothy Rolph
AU  - Mazen Noureddin
PY  - 2026
JO  - Hepatology
DO  - 10.1097/hep.0000000000001792
UR  - https://doi.org/10.1097/hep.0000000000001792
ER  -

APA

Chalasani, N., Tillman, E. J., Billes, S. K., Rolph, T., & Noureddin, M. (2026). Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH. Hepatology. https://doi.org/10.1097/hep.0000000000001792

Source records

crossref · retrieved 2026-11-11T01:57:17.191Z